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Despite current advancements in research and therapeutics, lung cancer remains the leading cause 25 
of cancer-related mortality worldwide. This is mainly due to the resistance that patients develop 26 
against chemotherapeutic agents over the course of treatment. In the context of non-small cell 27 
lung cancers (NSCLC) harboring EGFR oncogenic mutations, augmented levels of AXL and 28 
GAS6 have been found to drive resistance to EGFR tyrosine kinase inhibitors such as Erlotinib 29 
and Osimertinib in certain tumors with mesenchymal-like features.  By studying the ontogeny of 30 
AXL-positive cells, we have identified a novel non-genetic mechanism of drug resistance based 31 
on cell-state transition. We demonstrate that AXL-positive cells are already present as a sub-32 
population of cancer cells in Erlotinib-naïve tumors and tumor-derived cell lines, and that the 33 
expression of AXL is regulated through a stochastic mechanism centered on the epigenetic 34 
regulation of miR-335. The existence of a cell-intrinsic program through which AXL-35 
positive/Erlotinib-resistant cells emerge infers the need of treating tumors harboring EGFR-36 
oncogenic mutations upfront with combinatorial treatments targeting both AXL-negative and 37 





Each year, more than a million patients worldwide are diagnosed with non–small cell lung cancer 42 
(NSCLC) (Brose, Volpe et al. 2002, Samuels, Wang et al. 2004, Stephens, Hunter et al. 2004, 43 
Haber, Bell et al. 2005, Bean, Brennan et al. 2007, Pillai and Ramalingam 2012). In 2014, the 44 
discovery that EGFR-oncogenic mutations were present in 15-30% of NSCLC patients and that 45 
the vast majority of patients harboring such mutations are particularly sensitive to treatment with 46 
EGFR inhibitors (TKi) such as Erlotinib and Gefitinib was a critical breakthrough (Lynch, Bell et 47 
al. 2004, Paez, Janne et al. 2004).  The identification of these actionable EGFR-48 
oncogenic mutations revolutionized the management of NSCLC tumors from a predominantly 49 
clinical-pathological to a genotype-directed classification and therapeutic approach. Yet, the 50 
success of this biomarker-based targeted therapy has been hampered by the occurrence of drug 51 
resistance. In fact, within a year of treatment with EGFR TKIs, almost all patients experience 52 
relapse (Bell, Gore et al. 2005). 53 
  54 
The past 10 years have seen tremendous progress in our understanding of the multiple 55 
mechanisms that lead to acquired resistance against TKIs. Using both experimental systems and 56 
patient samples, secondary/gatekeeper mutations in EGFR (T790M), c-Met amplifications, PI3K 57 
mutations, and the acquisition of mesenchymal and small-cell lung cancer features have been 58 
identified and validated as molecular determinants of EGFR TKi resistance (Bell, Gore et al. 59 
2005, Engelman, Mukohara et al. 2006, Shaw, Yeap et al. 2009, Yao, Fenoglio et al. 2010, Shaw 60 
and Engelman 2016). More recently, the expression of AXL has also been reported as an 61 
additional mechanism of acquired resistance in EGFR TKi resistant tumors with mesenchymal-62 
like features (Zhang, Lee et al. 2012, Byers, Diao et al. 2013, Walter, Sjin et al. 2013, Elkabets, 63 
Pazarentzos et al. 2015). 64 
  65 
AXL is a member of the TAM (Tyro-AXL-Mer) receptor tyrosine kinase family. These receptors 66 
regulate a variety of cellular responses including cell survival, proliferation, motility, as well as 67 
differentiation (Zhang, Knyazev et al. 2008, Ghosh, Secreto et al. 2011, Ben-Batalla, Schultze et 68 
al. 2013). AXL is expressed in many embryonic tissues and participates in mesenchymal and 69 
neuronal development. In adult tissue, its expression is usually restricted to smooth muscle cells 70 
but it has been observed to be overexpressed in several human tumors of different tissue origins 71 
(Zhang, Knyazev et al. 2008, Ghosh, Secreto et al. 2011, Ben-Batalla, Schultze et al. 2013).  72 
 73 
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AXL possesses an extracellular domain with two N-terminal immunoglobulin (Ig)-like domains 74 
and two fibronectin type III (FNIII) repeats that bind to the growth-arrest-specific 6 (GAS6) 75 
ligand (O'Bryan, Frye et al. 1991, Mark, Chen et al. 1996, Nagata, Ohashi et al. 1996). The 76 
binding of AXL to GAS6 --upon its paracrine or autocrine secretion-- enables the trans-auto-77 
phosphorylation of AXL’s intracellular tyrosine kinase domain and, consequently, the activation 78 
of multiple downstream signaling cascades (Braunger, Schleithoff et al. 1997, Prasad, Rothlin et 79 
al. 2006).  80 
  81 
In the context of NSCLC, higher levels of AXL and GAS6 have been observed in tumors that 82 
developed resistance to Erlotinib and Osimertinib (Zhang, Lee et al. 2012, Byers, Diao et al. 83 
2013, Taniguchi, Yamada et al. 2019, Chen and Riess 2020). In these tumors, targeting AXL by 84 
either chemical or genetic inhibition restored Erlotinib sensitivity. Alternatively, forced 85 
expression of an active AXL kinase in Erlotinib-sensitive tumor cells was sufficient to induce 86 
Erlotinib resistance (Zhang, Lee et al. 2012). 87 
 88 
Despite these documented findings, the molecular mechanisms leading to the ontogeny of AXL-89 
positive cells remains poorly understood. Unlike other receptor tyrosine kinases, no mutations or 90 
amplifications of the AXL locus have been described in AXL-positive/Erlotinib-resistant cells 91 
(Wu, Liu et al. 2014). 92 
  93 
Here, we demonstrate that AXL-positive cells are already present in Erlotinib-naïve tumors and 94 
that they are generated via an epigenetic/stochastic mechanism. Consistent with this model, we 95 
found that the transition between AXL-positive and AXL-negative cells is highly plastic.  96 
 97 
This mechanism conceptually differs from previously described models of acquired or adaptive 98 
resistance based on the acquisition of secondary mutations, or drug-driven rewiring of signaling 99 
networks. The generation of AXL-positive cells is neither generated via genetic mutations nor 100 
dependent on the micro-environment or drug treatment (Bell, Gore et al. 2005, Engelman, 101 
Mukohara et al. 2006, Shaw, Yeap et al. 2009, Yao, Fenoglio et al. 2010, Shaw and Engelman 102 
2016). Also different from quiescent AKT1low cancer cells described by the Ramaswamy group, 103 
AXL-positive cells are actively dividing (Kabraji, Sole et al. 2017).  104 
 105 
At the molecular level, we showed that the generation of AXL-positive cells is centered on the 106 
methylation of a specific CpG island present in the promoter of MEST, a gene that contains the 107 
 5 
miRNA miR-335 in its second intron. In particular, we showed that forced down-regulation of 108 
miR-335 in AXL-negative cells was sufficient to increase the expression of AXL and to induce 109 
phenotypic and molecular features that are characteristic of AXL-positive cells, such as 110 
epithelial-to-mesenchymal transition and Erlotinib resistance. 111 
 112 
Altogether these observations define a novel mechanism that couples epigenetic/stochastic 113 
inheritance to the ontogeny of the AXL-positive/Erlotinib-resistant cells. This novel framework 114 
could inform the development of novel cancer treatments based on the targeting of both AXL-115 




AXL-positive cells are pre-existing in cell lines and tumors  120 
 121 
It has been shown that when non-small cell lung cancer (NSCLC)-derived cell lines harboring 122 
EGFR-oncogenic mutations are exposed to EGFR-TKIs like Erlotinib, populations of AXL-123 
positive/Erlotinib-resistant cells emerge with features similar to those observed in tumors that 124 
have developed Erlotinib treatment resistance in patients (Zhang, Lee et al. 2012). This is the case 125 
for the NSCLC derived cell lines H1650-M3 and PC14. These cells are derivative of H1650 and 126 
PC9 cells respectively, harbor EGFR oncogenic mutations, and were previously generated by 127 
culturing the parental cells with constant high concentrations of Erlotinib (Yao, Fenoglio et al. 128 
2010).  129 
 130 
We wondered if AXL-positive cells are present in tumors before treatment as well as in tumor-131 
derived cell lines and whether these cells bear phenotypic and molecular similarities to the AXL-132 
positive cells that are generated upon exposure to EGFR-TKI (Zhang, Lee et al. 2012). 133 
 134 
Given that AXL is a cell surface receptor, we utilized FACS sorting analysis with an antibody 135 
that recognizes an epitope localized within the N-terminal extra-cellular moiety of AXL to 136 
identify and separate putative AXL-positive cells. By using the AXL-positive cell lines, H1650-137 
M3 and PC14 as reference (Figure 1A and B), we observed the presence of AXL-positive cells in 138 
multiple Erlotinib-naïve cell populations (Figure 1B-D). The presence of these AXL-positive 139 
cells was not restricted to tumor-derived cell lines harboring EGFR-oncogenic mutations, as we 140 
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observed that a similar percentage of AXL-positive cells were present also in cell lines driven for 141 
example by mutant KRAS (i.e., A549) (Figure 1C-D).  142 
 143 
In tumors, the expression of AXL is often accompanied by the expression of its ligand, GAS6 144 
resulting in the constitutive activation of AXL and its downstream signaling pathways (i.e., AKT 145 
and ERK). We found that this was the case also in the pre-existing FACS-sorted AXL-positive 146 
cells. Our RT-PCR and western-blot analysis confirmed the high expression of AXL and GAS6 147 
in these cells (Figure 1D-F) and indicated that AXL, as well as AKT, were constitutively 148 
phosphorylated in AXL-positive cells (Figure 1F).  149 
 150 
To exclude the possibility that our observations were an artifact of our cell culture system and 151 
more importantly to test the relevance of our findings in patients, we performed similar analyses 152 
in five primary NSCLC tumors. To limit our analysis only to tumor cells, we analyzed AXL 153 
expression only in cells that were CD45-, CD31- and EPCAMmid/high. This FACS algorithm 154 
excludes bone marrow-derived cells, endothelial cells, and fibroblasts. Also in this case, we found 155 
that human primary drug-naïve tumors contained a subpopulation of cells with high expression of 156 
AXL and GAS6 (Figure 1G and H; Figure 1- figure supplement 1A).  157 
 158 
Pre-existing AXL-positive cells have phenotypic and molecular features of Erlotinib-159 
resistant cells 160 
 161 
Having shown the existence of AXL-positive cell populations in primary tumors and in tumor-162 
derived cell lines, next, we tested whether these cells had phenotypic and molecular features of 163 
Erlotinib resistant AXL-positive cells. We found that AXL-positive FACS-sorted cells from 164 
Erlotinib-naïve cell lines (i.e., PC9 AXL+ve) and AXL-positive cells that were generated upon 165 
Erlotinib-selection (i.e., PC14) had similar sensitivity to Erlotinib treatment with IC50 almost 3 166 
times higher than parental cells (i.e., PC9) (Figure 2A). To further investigate the contribution of 167 
pre-existing AXL+ cells to Erlotinib resistance, we did a cell lineage tracing experiment in which 168 
drug sensitivity was assessed after that AXL+/GFP+ cells were mixed with AXL-/GFP- negative 169 
cells in the approximate equal ratio. We observed a substantial increase in the representation of 170 
the AXL+ GFP+ cells upon Erlotinib treatment (Figure 2-figure supplement 1A-D). Because this 171 
study was conducted in a short period (96 hours after sorting), our data further solidify our 172 
conclusion that pre-existing AXL+ cells can be the main source of Erlotinib resistance. 173 
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To account for possible differences in growing conditions, as an alternative approach, we 174 
performed a colony assay in which AXL+ and AXL- cells were mixed with different 175 
representations. We found that the presence of AXL-positive cells resulted in a significantly 176 
higher number of drug-resistant colonies, compared with only AXL-negative cells (Figure 2-177 
figure supplement 2 A-B). 178 
 179 
Morphologically, the FACS-sorted AXL+ cells looked very similar to the AXL+ cells that 180 
emerged following Erlotinib treatment (PC14 and H1650-M3).  All possessed the morphological 181 
and molecular features of mesenchymal cells, including loss of cobblestone shape and increased 182 
stress fibers (Figure 2B and Figure2-figure supplement 2C) and differential expression of 183 
mesenchymal and epithelial markers (e.g., TGF-1, TGF-2, Slug, Twist, Vimentin and Zeb1) 184 
(Figure 2C; Figure 2-figure supplement 2D) (Zhang, Lee et al. 2012, Byers, Diao et al. 2013). 185 
These phenotypic features were driven by AXL because the inactivation of AXL in AXL-positive 186 
cells using the pharmacological inhibitor BMS-777607 resulted in the loss of the mesenchymal 187 
marker Vimentin and increased expression of E-cadherin (Figure 2-figure supplement 2E). 188 
 189 
Epithelial-to-mesenchymal transition can be induced by multiple cues, including the over-190 
expression of certain receptor tyrosine kinase receptors like AXL, c-MET, PDGFR; exposure to 191 
TGF-1, TGF-2; or hypoxia (Yao, Fenoglio et al. 2010, Wu, Hou et al. 2013, Zhang, Huang et 192 
al. 2013, Rankin, Fuh et al. 2014, Elkabets, Pazarentzos et al. 2015, Li, Dobbins et al. 2015). 193 
Hence, we wondered whether the expression of AXL was a common feature of all mesenchymal 194 
cells or if on the contrary was specific to a particular cell state. Hence, we analyzed the presence 195 
of AXL-positive cells in multiple tumor-derived cell lines and correlate their distribution with the 196 
mesenchymal status of the cells. Despite H1703, H1975 and H23 cells present with clear 197 
mesenchymal characteristics, AXL-positive cells were represented at a very low percentage in 198 
these cell lines and virtually absent in the H1703 cells (Figure 2-figure supplement 3A-C). Hence 199 
we concluded that while all mesenchymal cells share common characteristics such as increased 200 
stress fibers, increased motility, elongated shape, etc.; AXL-positive cells are a unique cell 201 
population with features that only partially overlap with other mesenchymal cells. 202 
 203 
AXL-positive cells are generated stochastically 204 
 205 
Cancer cells are characterized by intrinsic genetic instability that can give rise to clonal cell 206 
populations with distinctive genotypic and phenotypic qualities (Greaves and Maley 2012, 207 
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Barber, Davies et al. 2015). In addition, it has been shown that intra-tumor heterogeneity could be 208 
spurred by non-genetic determinants (Polyak and Weinberg 2009, Meacham and Morrison 2013). 209 
In this regard, Gupta et al. have suggested that cancer cells can oscillate stochastically among 210 
different cell states characterized by differential expression of the surface markers CD44 and 211 
CD24 (Gupta, Fillmore et al. 2011). More recently, the Haber group also showed that circulating 212 
tumor cells from ER+/HER- patients can be HER2- and HER2+, and readily interconvert from 213 
one state to the other within 4 doubling times (Jordan, Bardia et al. 2016). 214 
 215 
Here we tested if AXL-positive cells were generated stochastically. We reasoned that if the AXL-216 
positive cells were generated by mutations, it would be very unlikely that these mutations would 217 
occur in synchrony. If this was the case, then we would expect the percentages of AXL-positive 218 
cells to vary across clonal cell lines derived from a single AXL-negative cell (Figure 3A). On the 219 
other hand, if the AXL-positive cells were generated through a stochastic event, we instead would 220 
predict the percentages of AXL-positive cells to be similar in multiple clonal cell lines derived 221 
from a single AXL-negative cell (Figure 3B).  222 
 223 
To explore these two models, we derived isogenic cell lines from FACS sorted AXL-negative 224 
H1650 and HCC827 cells; allowed them to expand; and then assessed the frequency of AXL-225 
positive cells from four, single-cell derived clonal cell lines. We observed a very similar 226 
percentage of AXL-positive cells in the parental cells as well as in the single-cell derived clonal 227 
cell lines (Figure 3C-D; Figure 3-figure supplement 1A and B). Based on this finding, we 228 
concluded that AXL-positive cells are most likely generated from AXL-negative cells via a non-229 
genetic, stochastic mechanism.  230 
 231 
To further confirm this observation and to improve our understanding of the cell-state plasticity 232 
of AXL-positive and AXL-negative cells, we sorted pure AXL-positive and AXL-negative cells 233 
from the H1650 cell line and analyzed the distribution of AXL-positive and AXL-negative 234 
progeny of cells over time (Figure 3E). We found that within three weeks, the AXL-negative cells 235 
could regenerate cell populations with the same percentage of AXL-positive and AXL-negative 236 
cells as the parental cell line. Interestingly, we observed that even though the AXL-positive cells 237 
took a longer time to do so (18 weeks), they too were able to regenerate a progeny population 238 
with the same percentages of AXL-positive and AXL-negative as present in the parental cell line. 239 
To exclude the possibility that this finding was the result of competition among clones driven by 240 
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genetic mutations, we repeated the same experiments using a single-cell derived cell line (e.g., 241 
H1650- clone 2). In this case, a nearly identical trend was recapitulated (Figure 3F).  242 
 243 
miRNA profiling of AXL-positive cells revealed a unique miRNA signature 244 
 245 
Among the many possible regulators of cell-state plasticity, we sought to investigate whether 246 
microRNAs (miRNAs) were involved in modulating the ontogeny of AXL-positive cells (Garzon, 247 
Marcucci et al. 2010). 248 
 249 
miRNAs are small (~22 nt) non-coding RNAs constituting a novel class of gene regulators that 250 
post-transcriptionally repress gene expression by initiating the degradation or blocking translation 251 
of target mRNAs (Lau, Lim et al. 2001, Lee and Ambros 2001, Ambros, Bartel et al. 2003). More 252 
than 1000 unique, mature miRNAs have been identified in the human genome (Griffiths-Jones 253 
2004) and each may regulate up to 200 mRNAs (Lewis, Shih et al. 2003, Betel, Wilson et al. 254 
2008). It is estimated that roughly 30% of all human gene transcripts are targeted by miRNAs, 255 
implicating them in the regulation of virtually all cellular processes. 256 
 257 
We generated miRNA expression profiles from the AXL-positive H1650-M3 and parental AXL-258 
negative H1650 cells by constructing small RNA libraries. These libraries were deep sequenced 259 
using the Illumina platform. Sequence reads were mapped to the human genome using a 260 
customized bioinformatics pipeline. Reads were annotated by BLAT (Kent 2002) to a unified 261 
database containing entries for human small RNAs from miRBase (Griffiths-Jones 2004), 262 
NONCODE (Liu, Bai et al. 2005), tRNAs in The RNA Modification Database (Limbach, Crain et 263 
al. 1994), and rRNA entries in the Entrez Nucleotide Database (Schuler, Epstein et al. 1996). Our 264 
previous experience performing comparative analysis informed our decision to use an arbitrary 265 
cut-off of a minimum of 1000 reads and >2 fold differential expression. Using these criteria, we 266 
identified 20 miRNAs that were up-regulated and 19 miRNAs that were down-regulated in the 267 
AXL-positive H1650-M3 cells compared to the AXL-negative H1650 cells (Figure 4A and B). 268 
Differential miRNA expression levels were independently validated by quantitative stem-loop 269 
RT-PCR (qRT-PCR) in the AXL-negative (H1650) and AXL-positive (H1650-M3) cell lines 270 
(Figure 4C). Apart from let7c, the differential miRNA expression patterns of all miRNAs 271 
identified by our deep sequencing analysis were confirmed (Figure 4C).  272 
 273 
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Although none of the identified miRNAs were predicted to target AXL, we were intrigued by the 274 
differential expression of miR-335 we observed in AXL-positive compared to AXL-negative 275 
cells. It has been reported that miR-335 suppresses a mesenchymal-like state and metastatic 276 
dissemination by targeting a diverse set of genes regulating cell migration, extracellular matrix 277 
remodeling, cell self-renewal, and epigenetic reprogramming (Tavazoie, Alarcon et al. 2008) 278 
(Figure 1D). Among them, of particular interest was the regulation of the TGF-axis by miR-279 
335. In fact, TGF-is a well-known regulator of AXL and AXL activity (Lynch, Fay et al. 2012). 280 
Furthermore, the TGF-axis has also been shown to suppress the expression of multiple miRNAs 281 
that we found to be down-regulated in AXL-positive cells (Gregory, Bracken et al. 2011, Yang, 282 
Li et al. 2012, Kato, Dang et al. 2013). Altogether these findings let us to hypothesize that 283 
differentially expressed miRNAs in AXL-positive cells could be part of a hierarchically 284 
organized miRNA cluster primed by miR-335 and that the regulation of miR-335 could play a 285 
major role in the ontogeny of AXL-positive cells.  286 
 287 
As a first step to test this possibility, we determined how general was the decrease in miR-335 288 
expression we observed in AXL-positive cells. To this end, we examined the expression of miR-289 
335 in: 1) Erlotinib resistant H1650-M3 and PC14 cells (Figure 4E), 2) FACS sorted AXL-290 
positive and AXL-negative cells from H1650 and HCC827 cell lines (Figure 4F), as well as 3) 291 
FACS sorted cells from four human primary NSCLC tumors (Figure 4G). In all these cases, when 292 
we measured the expression of miR-335 by qRT-PCR, we consistently found that miR-335 levels 293 
were decreased in all AXL-positive cells (Figure 4E-G). 294 
 295 
To verify that miR-335 was active in AXL-positive cells, next, we compared the expression 296 
levels of known and predicted miR-335 targets. RT-PCR analysis showed that the miR-335 297 
targets SOX4, TNC, COL1A1, PTPRN2, MERTK, PLCB1, LAMB2, FGF2, JAG1, BMI1, 298 
SMARCA2, MAX were expressed at higher levels in AXL-positive; miR-335 low cells (H1650-299 
M3) compared to AXL-negative;miR-335 high cells (H1650) (Figure 4D). 300 
 301 
We previously have shown that AXL-positive cells have increased activation of the TGF-beta 302 
pathway (See figure 2). To determine if miR-335 was sufficient to regulate the activity of the 303 
TGF-pathway, we inactivated miR-335 by transfecting AXL-negative cells with three 304 
independent Antagomirs and assessed the expression of TGF- 1 and 2 and some of their 305 
downstream targets (e.g., Vim, Ecadh, Snail) by RT-PCR. We found that the Antagomirs 306 
treatment decreased the expression of miR-335 (Figure 4-figure supplement 1A) and of its targets 307 
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(Figure 4-figure supplement 1B) as well as of TGF- 1/ 2 (Figure 4-figure supplement 1C) and of 308 
the TGF- target genes VIM, Ecadh, SNAI, SLUG, etc. compared to control (Figure 5D).  309 
 310 
As reported in the literature, we also observed the majority of miRNAs we observed to be 311 
differentially expressed in AXL-positive and AXL-negative cells to be regulated by TGF- 1/ 2 312 
except for MiR-335 (Figure 4H and I). Consistent with TGF-beta being regulated by miR-335, we 313 
also found that inactivation of miR-335 was sufficient to reduce the expression of these miRNAs 314 
(miR-20a, miR-34a, miR-200c, etc.) but to increase the expression of miR-143 and miR-195, 315 
which were expressed at higher levels in AXL-positive cells when compared to AXL-negative 316 
cells (Figure 4J). 317 
 318 
miR-335 regulates the ontogeny of AXL-positive cells.  319 
 320 
Our data indicated that miR-335 regulates the expression of key molecular determinants of the 321 
AXL-positive state. To test if miR-335 could regulate the ontogeny of AXL-positive cells, we 322 
decreased the expression of miR-335 using Antagomir treatment in multiple AXL-negative cells 323 
and analyzed the morphology, the expression of signature genes as well as their resistance to 324 
EFGR Tki. 325 
 326 
We observed that treatment of AXL-negative cell lines (H1650 and PC9) with a miR-335 327 
Antagomir resulted in a reduction of miR-335 expression (Figure 5A) and an increased 328 
expression of AXL-positive cells (Figure 5B; Figure 5-figure supplement 1A). This was 329 
accompanied by epithelial-to-mesenchymal transition manifested by loss of the classic 330 
cobblestone appearance of epithelial cells (Figure 5C) and changes in EMT molecular markers 331 
(Figure 5D).  332 
 333 
In a standard drug sensitivity assay, we observed that treatment with miR-335 Antagomir also 334 
increased the resistance of cells to Erlotinib treatment to levels similar to what we observed when 335 
we tested the AXL-positive cell lines we derived by Erlotinib selection (Figure 5 E and F).   336 
 337 
To provide additional proof that inhibition of miR-335 was sufficient for the generation of AXL-338 
positive cells, we utilized CRISPR-CAS9 gene editing as an orthogonal approach. Also in this 339 
case and consistent with our previous results, genetic inactivation of miR-335 resulted in the 340 
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acquisition of phenotypic and molecular characteristics of AXL-positive cells (Figure 5-figure 341 
supplement 2A-C). 342 
 343 
Interestingly, when we express miR-335 mimic oligonucleotides in the AXL+ cells H1650-M3 344 
and PC14 we observed a dramatic decrease in cell viability (Figure 5G-H). To exclude this was 345 
due to a non-specific effect of miRNA mimic oligonucleotide transfection, we repeated the same 346 
experiment by transfecting an unrelated miRNA (Figure 5G-H and Figure 5-figure supplement 347 
3A-B).  In this case, there was no difference in the cell viability compared to control (transfection 348 
agent). Hence, the transition of cells into AXL+ cell state induced the rewiring of cell signalings 349 
to which cells become “addicted”.  350 
 351 
Altogether, these observations indicate that miR-335 serves as a critical regulator of the 352 
interconversion of AXL-negative and AXL-positive cell states beyond its well-studied role in the 353 
regulation of metastasis (Tavazoie, Alarcon et al. 2008).  354 
 355 
Methylation of MEST isoform 2 promoter modulates miR-335 expression in AXL-positive 356 
cells  357 
 358 
The miR-335 encoding sequence resides in the second intron of the mesoderm-specific transcript 359 
homolog (MEST)/paternally expressed 1 (PEG1) gene located on chromosome 7q32. In humans, 360 
two distinct CpG islands have been identified in the promoters of MEST (Figure 6A) (Png, 361 
Yoshida et al. 2011, Dohi, Yasui et al. 2013). To investigate the possible epigenetic regulation of 362 
miR-335, we analyzed levels of MEST CpG island 1 and 2 methylation by bisulfite sequencing, 363 
methylation-specific RT-PCR, as well as qRT-PCR in AXL-positive H1650-M3 and AXL-364 
negative H1650 cells (Figure 6A and B). We found that although no significant differences were 365 
observed in the methylation of CpG island 2, CpG island 1 was differentially methylated in the 366 
AXL-positive H1650-M3 cells, and associated with higher expression of MEST isoform 1 and 367 
decreased expression of miR-335 (Figure 6B, Figure 6-figure supplement 1A).  368 
 369 
We extended these analyses to include AXL FACS sorted cell lines (H1650 and PC9) and human 370 
NSCLC tumor-derived cells. Again, we found that all AXL-positive cells displayed increased 371 
methylation of CpG island 1 relative to AXL-negative cells (Figure 6C and D; Figure 6-figure 372 
supplement 1B).  373 
 374 
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To establish the functional relevance of the hyper-methylation of the MEST isoform 2 promoter, 375 
we treated AXL-negative H1650 cells and AXL-positive H1650-M3 cells with the DNA 376 
methylation inhibitor 5-aza-2’-deoxycytidine (5-Aza-dC). Consistent with the observation that re-377 
expression of mirR-335 in AXL+ cells resulted in cell death, long-term treatment with 5-Aza-dC 378 
in AXL+ cells H1650-M3 and PC14 revealed an increased sensitivity of these cells to the drug 379 
treatment when compared to the AXL- cells H1650 and PC9 (Figure 6-figure supplement C-D). 380 
To determine if this could be due to changes in the methylation of MEST promoter, we examined 381 
the methylation status of MEST CpG island 1 upon short treatment (36 hours) with 5-Aza-dC in 382 
H1650 and H1650-M3 cells. We observed a dose-dependent change in the methylation of CpG 383 
island 1 and, consistent with the role of CpG island hypermethylation in gene silencing, increased 384 
expression of miR-335 in AXL-positive cells (Figure 6E and F). Importantly, no differences were 385 
observed in the AXL-negative H1650 cells upon treatment with 5-Aza-dC compared to the 386 
control. Following the proposed role of miR-335 in the regulation of AXL, we also observed a 387 
decrease in AXL mRNA expression (Figure 6-Figure supplement 1C). These changes were most 388 
likely due to increased miR-335 levels as inhibition of miR-335 by Antagomir treatment impeded 389 
the observed decrease in the number of AXL-positive cells in H1650-M3 cells (AXL-positive) 390 
treated by 5-Aza-dC (Figure 6G).  391 
 392 
To further characterize a possible role of miR-335/MEST DNA methylation in Erlotinib 393 
resistance, we performed a drug sensitivity assay in which we combined 5-Aza-dC and Erlotinib 394 
treatment. Consistent with 5-Aza-dC decreasing MEST promoter methylation and the viability of 395 
AXL-positive cells (Figure 6E-G), we observed a decrease in AXL-positive cells in H1650 cells 396 
upon 5-Aza-dC treatment (Figure 6-Figure supplement 1D) and overall increased sensitivity of 397 
H1650 cells to Erlotinib (Figure 6H).  398 
 399 
Based on these observations, we concluded that differential miR-335 promoter methylation is 400 
responsible for the decreased expression of miR-335 observed in AXL-positive cells and that the 401 
transition between the AXL-positive and AXL-negative cell states as well as their differential 402 
resistance to EGFR TKi is regulated epigenetically.  403 




Drug resistance continues to be a major hurdle that oncologists face in treating cancer patients. 407 
Although the genetic diversity of tumors has been proposed to drive the acquisition of drug 408 
resistance; emerging data indicate that also non-genetic determinants could be equally significant 409 
(Brock, Chang et al. 2009). These include the interaction of a tumor with its micro-environment 410 
as well as the occurrence of cell-intrinsic molecular mechanisms such as epigenetic changes 411 
(Brock, Chang et al. 2009, Muranen, Selfors et al. 2012).  412 
 413 
In the case of lung tumors driven by oncogenic-EFGR mutations, it has been observed that 414 
approximately 15% of tumors that become resistant to EGFR TKi are characterized by 415 
mesenchymal-like features and higher expression of AXL. In these tumors inhibition of AXL 416 
restore the sensitivity to EGFR TKi (Zhang, Lee et al. 2012, Taniguchi, Yamada et al. 2019). In 417 
contrast to other mechanisms of resistance to EGFR TKi, in these tumor cells, AXL was neither 418 
mutated, amplified or its expression driven by EGFR TKi treatment as in the case of the 419 
persistent cells originally described by Settleman et al. (Sharma, Lee et al. 2010).   420 
 421 
Here we described a novel molecular mechanism driving the ontogeny of AXL-positive EGFR 422 
TKi resistant cells based on the stochastic fluctuation of cancer cells between an AXL-negative 423 
state characterized by epithelial-like features and an AXL-positive state in which cells are 424 
mesenchymal and have an increased resistance to EGFR TKi (Figure 7). The switch between 425 
these two cell-states is restricted by miR-335 as all AXL-positive cells we examined were 426 
characterized by a decreased expression of miR-335 and that inactivation of miR-335 decreased 427 
the number of AXL-positive cells and reverted AXL-positive cells into AXL-negative cells.  428 
 429 
Although miR-335 restricts the transition of AXL-positive into AXL-negative cells, AXL mRNA 430 
does not contain a miR-335 seeding sequence, which means it is unlikely to be a direct target of 431 
miR-335. Yet, miR-335 has been previously shown to regulate the expression of a multitude of 432 
signaling pathways including components of the TGF- axis. The regulation of the TGF- axis 433 
by miR-335 is of particular interest because AXL is a known downstream target of TGF-; hence 434 
suggesting a possible molecular linking AXL and miR-335 (Bauer, Zagorska et al. 2012).  435 
 436 
The inhibition of the TGF- signaling pathway by miR-335 is particularly interesting also 437 
because exposure to TGF- regulate the expression of several of the miRNAs associated with the 438 
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AXL-positive state, such as miR-20a, miR-34a, miR-200c, etc. Among them of particular 439 
significance were the mir-200 family members, as they not only induce EMT but also resistance 440 
to Erlotinib (Brabletz and Brabletz 2010). 441 
 442 
Lastly, miR-335 is among approximately 50 miRNAs that are regulated epigenetically by DNA 443 
methylation of CpG islands within promoter regions (Lujambio and Esteller 2007). The 444 
epigenetic regulation of miR335 is particularly interesting in light of the observation that AXL-445 
positive and AXL-negative cell populations are highly dynamic. AXL FACS-sorted cells can 446 
interconvert until the same two cell state distribution observed in the parental cell population is 447 
reached (Figure 3E). Notably, we observed the time required for AXL-positive and AXL-negative 448 
cell populations to reach equilibrium is different. While within a few weeks the AXL-negative 449 
cells generated a population of cells with the same distribution of AXL-positive and AXL-450 
negative cells as was observed in the parental cell line; it took the AXL-positive cells a couple of 451 
months to reach this equilibrium. At this time, we don’t have a clear molecular mechanism 452 
explaining these differences, yet it is tentative to hypothesize that --given the stochastic regulation 453 
of miR335-- because the AXL-positive cells grow slower than AXL-negative cells, it will take a 454 
longer time for the former to switch state. Alternatively, it is tempting to postulate that the inter-455 
conversion between the two cell states could be regulated by enzymatic activities occurring at 456 
different rates. This hypothesis is informed by the possibility that the de-methylation rate of the 457 
CpG1 on the miR-335 promoter could occur less efficiently than its methylation.  458 
 459 
One important feature of AXL-positive cells is their intrinsic resistance to EGFR TKi. This 460 
implies that because AXL-positive cells could revert back to an AXL-negative state, the drug 461 
resistance observed in AXL-positive tumors, although heritable, is not a stable trait in the 462 
population. Consequently, as shown in the schematic in Figure 7, AXL-negative cells could 463 
hypothetically emerge over time following drug removal. This phenomenon is in principle similar 464 
to the observation that certain Erlotinib-resistant tumors expressing neuroendocrine markers can 465 
revert to an epithelial-like state over time upon interruption of the drug treatment (Niederst, 466 
Sequist et al. 2015).  467 
 468 
Nevertheless, the AXL-positive cells that survived to the drug treatment can accumulate novel 469 
genetic mutations that can alter the innate equilibrium between AXL-positive and AXL-negative, 470 
and, consequently, produce tumors that are stable AXL-positive state (Figure 7). This explanation 471 
seems to be true for certain clonal populations, including the H1650-M3 and PC14 cells that were 472 
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selected to grow and expand in the presence of high Erlotinib concentrations. In fact, these cell 473 
lines maintain features associated with the AXL-positive cell state even in the absence of drug 474 
treatment. Interestingly, we have recently observed that TGF-beta by repressing DNA repair 475 
could spur the accumulation of mutations and accelerate the clonal evolution of tumors (Pal, 476 
Pertot et al. 2017).  477 
 478 
Interestingly, the reactivation of miR-335 resulted in a dramatic decrease in the viability of AXL+ 479 
cells suggesting that the cells transiting into AXL+ cells are addicted to specific singling, 480 
regulated by miR-335. Altogether these findings have important clinical implications. They 481 
predict that treatments based only on targeting the epithelial, AXL-negative cells, such as in the 482 
case of Erlotinib and Osimertinib treatments, will be insufficient and poised to fail. Yet, 483 
combinatorial treatments targeting both cell states could increase the sensitivity of drug treatment 484 
and slow or prevent the acquisition of tumor resistance.  This could be the case of co-treatment of 485 
tumors with EGFR TKi and AXL inhibitors or EGFR TKi and 5-Aza-dC. Of note, our in vitro 486 
studies indicated that the concentration of 5-Aza-dC to which AXL-positive cells are sensitive are 487 
well within the 5-Aza-dC blood concentrations observed in clinical trials for the treatment of 488 
different cancer types (Karahoca and Momparler 2013). 489 
  490 
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MATERIALS AND METHODS 491 
Cell culture 492 
H1650, HCC4006, HCC827, A549, H358, and H2228 cell lines were purchased from American 493 
Type Culture Collection. All cell lines were authenticated through Short Tandem Repeat (STR) 494 
profiling and regularly tested for mycoplasma. The PC14 cell line was obtained by Dr. Kazuto 495 
Nisho (National Cancer Center Hospital, Tokyo). H1650-M3 cells were generated by culturing 496 
the H1650 cell line in the presence of a constant high concentration of Erlotinib as previously 497 
described (Yao et al.). All cell lines were maintained in RPMI GlutaMAX (Invitrogen) containing 498 
5% Fetal Bovine Serum. The culture medium was supplemented with 100 units/ml of penicillin 499 
and 100 ug/ml of Streptomycin (Invitrogen). All cell lines were cultured at 37oC and 5% CO2. 500 
 501 
Generation of isogenic clones: 502 
H1650 cells were serially diluted in 96 wells such that one well contains one cell. They were then 503 
grown for 2 months before the experiments. 504 
 505 
TGF-β treatment 506 
Cells were treated with rhTGFβ1 and rhTGFβ2 (R&D systems, Minneapolis, MN) 1 ng/ml each 507 
in complete media, for 72 hrs. Following treatment, the cells were harvested for RNA preparation 508 
and qRT-PCR, for immunoblotting, or for cell cycle analysis. 509 
  510 
TGF-β inhibitor treatment  511 
For treatment with LY2157299 (20 μM) (TGFBR1 kinase inhibitor, Selleckchem, Houston, TX), 512 
300,000 H1650-M3 cells were plated in a 6 cm2 plate. The inhibitor was added the next day and 513 
the mixture was incubated for 3–5 days for LY2157299. The cells were lysed with TRIzol and 514 
processed for RNA preparation.  515 
 516 
Drug treatment 517 
To determine IC50 values for various drugs (Erlotinib and BMS-777607), the cells were plated in 518 
96-well plates at 1000 cells/well. The next day, individual drugs were added to the wells at the 519 
indicated concentrations and incubated for 5 days. The plates were then washed once with PBS, 520 
fixed with 3.7% formaldehyde and stained with Crystal violet. Each stained well was de-stained 521 
in 50-100 µl of 10% acetic acid and the absorbance was read in a spectrophotometer at 590 nm.  522 
 523 
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Long term drug treatment to generate persisters 524 
H1650-M3 cells were generated according to the protocol previously described by Yao et al (Yao 525 
et al.)  526 
 527 
RNAi Transfection, RNA extraction and quantitative Real-Time PCR 528 
RNAi transfection was performed using Lipofectamine™ 2000 (Invitrogen) as per the 529 
manufacturer’s protocol. Unless otherwise indicated, total RNA was collected 72 hours after 530 
transfection. Total RNA was extracted using Trizol (Life technologies). Removal of 531 
contaminating genomic DNA was performed by incubation with RQ1 RNase-Free DNase 532 
(Promega) for 30 min. 1000ng total RNA was reverse transcribed using ImProm-II reverse 533 
transcriptase and Oligo-dT primers. Quantitative PCR was carried out using Power SYBR Green 534 
PCR master mix on a 7900HT Fast Real-Time System (Applied Biosystems) or QuantStudio-6 535 
Real-Time System (Applied Biosystems). Power SYBR Green Cells-to-Ct kit was used to 536 
perform quantitative PCR on 10,000 cells sorted from tumors. Analyses were done in triplicate 537 
and Actin or GAPDH was used as a reference gene. A complete list of primer sequences is 538 
supplied in Supplementary file 1. 539 
 540 
Lentiviral infection 541 
Packaging cells HEK293T in passage 6 were seeded evenly at density 1-2×106 cells per 10 cm 542 
plate and incubated in DMEM supplemented with 10% FBS in the incubator, at 5% CO2 and 543 
37˚C for 20 hr. When they reached 70% confluency the media was changed 1hr before the 544 
transfection to a final volume of 10 mL. The mixture of 2 tubes, each with 500 µL of warm 545 
OptiMEM media was prepared. In one tube 25 µL of lipofectamine 2000 transfection reagent 546 
(Thermo Fisher cat # 11668019) was added and incubated for 5 min. To the second tube, a mix of 547 
plasmids was added - 10 µg pLenti CMV Puro DEST (w118-1) eGFP (Addgene Plasmid 548 
#107505), 6 µg of psPAX2, and 3 µg of pMD2.G plasmid. Tube 1 was mixed into tube 2 to form 549 
a transfection mixture and incubated for 20 min at room temperature. The mixture was dropwise 550 
to HEK293T cells and plates were incubated overnight. After 18hr the media was changed to 10 551 
mL of fresh DMEM with 10% FBS and plates were incubated for the next 48hr before the 552 
collection and filtering of the supernatant through a 0.45 µm filter was performed. Polybrene 553 
reagent (8 µg/mL) was added to the virus before infecting PC9 and H1650 cells for 24h. The flow 554 





miRNA analysis 559 
Total RNA was extracted using miRCURY™RNA isolation kit- cell & plant (Exiqon) according 560 
to manufacturer’s instructions. On-column removal of genomic DNA was performed using RQ1 561 
RNase-Free DNase (Promega). cDNA synthesis was performed using miRCURY LNA Universal 562 
RT microRNA PCR, Polyadenylation and cDNA synthesis kit (Exiqon; 203300) and miRCURY 563 
LNA Universal RT microRNA PCR SYBR green master mix was used for quantitative real-time 564 
PCR analysis. U6 snRNA was used as a reference gene. A complete list of primer sequences is 565 
supplied in Supplementary file 1. 566 
 567 
Methylation-specific RT-PCR, QPCR and bisulfite sequencing 568 
1 µg genomic DNA was pretreated with sodium hydroxide for 15 minutes at 37oC followed by 569 
incubation with hydroquinone (Sigma) and sodium metabisulfite (Sigma) for 16 hours at 50oC. 570 
The bisulfite modified DNA was subsequently purified using Wizard DNA Clean-up system 571 
(Promega). Genomic DNA from in vitro methylated Jurkat cells was (Active Motif) served as 572 
positive control and genomic DNA from H1993 cells served as a negative control. RT-PCR 573 
analysis was performed using Immolase DNA polymerase (Bioline) and fragments were 574 
separated on 2% agarose gels. Takara Episcope MSP kit was used for performing quantitative 575 
RT-PCR on a 7900HT Fast Real-Time System (Applied Biosystems). For analysis by bisulfite 576 
sequencing, fragments were cloned into the pGEM®-T Easy Vector (Promega) and 20 colonies 577 
from each sample were sequenced.  578 
 579 
Immunofluorescence 580 
AXL –ve and AXL-positive cells from H1650 and PC9 were FACS-sorted and cultured for 2 581 
days in an 8-well chamber slide system (LAB-TEK, Thermo Fisher Scientific). H1650, H1650-582 
M3, PC9 and PC14 cells were grown on glass coverslips in a 24-well Petri dish. Cells were fixed 583 
with 4% paraformaldehyde and permeabilized in 0.1% Triton X-100 in PBS for 10 minutes. 584 
Fixed cells were washed three times in PBS and blocked with 1% BSA in PBS for 1 hour. After 585 
washing three times with PBS, the cells were incubated with Alexa-Fluor 488 Phalloidin for 30 586 
min at room temperature. DAPI was used for nuclear staining. The stained cells were mounted 587 
with a Vectashield mounting medium (Vector Laboratories, Burlingame, California) and analyzed 588 
using a confocal microscope. 589 
 590 
Immunoprecipitation and Western Blot Analysis 591 
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Total cell lysates were obtained by lysing cells in modified denaturing buffer (50mM Tris-Cl pH 592 
7.5, 1 mM EDTA, 1 mM EGTA 1% Triton-X, 0.27M Sucrose, 1% β-mercaptoethanol) with 593 
protease inhibitor tablets and phosphatase inhibitors (10mM NaF, 1mM PMSF, 1mM Na3VO4). 594 
Lysate were incubated on ice for 30 min, mixed end-to-end at 4C for 30 min and then centrifuged 595 
at 13,000g for 30 min to remove debris. 1500 µg total protein lysate was 100ul slurry of pre-596 
cleared with Protein G agarose beads (Promega), followed by overnight incubation with AXL 597 
antibody (2ug Ab/ 100 ul lysate). Immunocomplexes were pulled down by incubating with 100ul 598 
slurry of pre-cleared with Protein G agarose beads. Immunoprecipitation complex and 10% lysate 599 
inputs were separated on 8% polyacrylamide gels, transferred to a nitrocellulose membrane, and 600 
blotted overnight with antibody against AXL, Phospho-AXL, Phospho-Tyrosine. β-tubulin was 601 
used as a loading control.   602 
 603 
Flow cytometry 604 
Cells were dissociated using TrypLE (Invitrogen) and washed with cold PBS containing 5% Fetal 605 
Bovine Serum. Resuspended cells were filtered through a 40-micron mesh to generate single-cell 606 
suspension and incubated with directly conjugated fluorescent antibodies to the desired antigens 607 
for 20 minutes on ice in the dark and subsequently washed 3 times with cold PBS pH 7.2.  608 
Analysis of AXL-negative and AXL-positive cell populations was performed on the LSRII (BD 609 
Biosciences). A total of 20,000 cells were analyzed using the FACSDiva 6.0 software (BD 610 
Biosciences). Isolation of AXL-negative and AXL-positive cells were done by Fluorescent 611 
Activated Cell Sorting performed on the Aria II (BD Biosciences).  For sorting cells from tumor, 612 
we stained a single-cell suspension derived from tumors with CD45, CD31, EpCAM and AXL 613 
antibodies. Based on the isotype staining, we gated the CD45-/ CD31-/ EpCAM mid/high population 614 
and then gated the desired AXL-negative and AXL-positive populations from the EpCAM mid/high 615 
population. 616 
 617 
Statistical analysis 618 
Data are represented as mean ± SD. Statistical analysis of experimental data was conducted using 619 
GraphPad Prism 7.0 software (San Diego, CA, USA). Student’s t-test (two-tailed) was used for 620 
two-group comparisons. Spearman’s rank test was used to measure the correlation between two 621 
variables.  P< 0.05 was considered statistically significant. 622 
 623 
Patient Study Details: 624 
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The collection of human lung tissue samples and blood for this study was covered by Northwell 625 
Health/ Cold Spring Harbor Laboratory IRB #TDP-TAP 1607 (Raffaella Sordella/10/11/16 ). The 626 
samples were acquired from patients already undergoing thoracic procedures (e.g. surgical tumor 627 
resection, biopsy) at Huntington Hospital. All study participants provided informed consent for 628 
the use of their lung tissue and blood for research purposes. Participants were informed of study 629 
aims, the potential risks and benefits of participation, and that any discoveries facilitated by the 630 
analysis of their tissues might be published. The participants were informed that their names 631 
would not be associated their samples in any publication or presentation of research findings. 632 
 633 
Reagents 634 
Recombinant human TGF-1 and TGF-2 was purchased from R&D Systems. miR-335 635 
antagomirs were obtained from the following companies: antagomir 1 from Ambion; antagomir 2 636 
from Exiqon (miRCURY LNA microRNA Power Inhibitor; 4100464-002) and antagomir 3 from 637 
Thermo Scientific Dharmacon (miRIDIAN hairpin inhibitor; IH-300708-07). miR-335 Mimic 638 
oligonucleotide was obtained from Exiqon (473600-001). The following chemical reagents were 639 
used for cell treatment: Erlotinib Hydrochloride 99% from LGM Pharmaceutical Inc, pyridone 6 640 
(P6) from Calbiochem, Trichlostatin (TSA) and 5-aza-2-deoxycytidine from Sigma-Aldrich. 641 
 642 
Antibodies 643 
For Flow Cytometry 644 
APC anti-human AXL antibody (R & D Systems); cat # FAB154A 645 
Alexa Fluor 488 anti-human AXL (R & D Systems); cat # FAB154G 646 
PE-CF594 anti-human CD45 antibody (BD Biosciences); cat. # 562279 647 
BV421 anti-human CD31 antibody (BD Biosciences); cat # 564089 648 
Alexa Fluor 488 anti-human CD326 (Ep-CAM) antibody (BioLegend); cat # 324210  649 
 650 
For Immunofluorescence 651 
Alexa Fluor 488 Phalloidin (Thermo Fisher); cat # A12379 652 
 653 
For Immunoprecipitation and Immunoblot analysis 654 
AXL M-20 goat polyclonal IgG (SCBT); cat. # sc-1097. Currently discontinued. 655 
Anti-alpha-tubulin antibody (Millipore) cat. # MABT205 656 
Phospho- Tyr PY20 mouse monoclonal IgG (SCBT); cat. # sc-508 657 
Phospho-AXL mouse monoclonal IgG (R & D Biosystems); cat. # MAB6965 658 
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Anti-Gas6 Antibody (A-9): mouse monoclonal IgG (SCBT); cat. # sc-376087 659 
GAPDH mouse monoclonal IgG (R & D Biosystems); cat. # MAB5718 660 
Ras-GAP goat polyclonal IgG (R & D Biosystems); cat. # AF5094 661 
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FIGURE LEGENDS 919 
 920 
Figure 1: AXL-positive cells are pre-existing in cell lines and tumors. 921 
A) Immunoblot analysis of AXL in AXL-positive cells (H1650-M3 and PC14) and AXL –ve 922 
cells (H1650 and PC9). -Tubulin is used as a loading control. B) Flow cytometry-based analysis 923 
of surface expression of AXL in the AXL-positive cell lines (H1650-M3 and PC14) and AXL –ve 924 
cells (H1650 and PC9). Monoclonal antibody against the N-terminal of AXL was used for the 925 
FACS analysis. Isotype control was used for identifying the AXL-negative population. C) The 926 
chart represents the percentage of AXL-positive cells present in Erlotinib resistant and Erlotinib 927 
naïve cell lines. Erlotinib resistant cell lines are indicated in red, Erlotinib naïve EGFR mutant 928 
cell lines are indicated in blue, and Erlotinib naïve EGFR WT cell lines are indicated in green. 929 
Each bar represents mean ± SD of 3 replicates from two independent experiments. D) The chart 930 
represents relative AXL mRNA expression in the indicated cell lines or cells sorted based on 931 
surface expression of AXL. Expression in AXL-positive cells was calculated relative to its 932 
expression in AXL-negative control cells. mRNA expression was quantified by SYBR-green-933 
based RT-qPCR. Each bar represents mean ± SD of 3 replicates from two independent 934 
experiments.  (p-value *** < 0.0005, **** < 0.00005, unpaired t-test). E) The chart represents 935 
relative Gas6 mRNA expression in the indicated cell lines or cells sorted based on surface 936 
expression of AXL. Expression in AXL-positive cells was calculated relative to its expression in 937 
AXL-negative control cells. mRNA expression was quantified by SYBR-green-based RT-qPCR. 938 
Each bar represents mean ± SD of 3 replicates from two independent experiments.  (p-value *< 939 
0.05, ** < 0.005, unpaired t-test). F) On the left panel, immunoblot analysis of AXL, GAS6, 940 
p120 RASGAP (loading control), p-AKT and AKT in AXL –ve (PC9) and AXL-positive (PC14) 941 
cells. On the right, cell extracts were immunoprecipitated with anti-AXL antibody and 942 
immunoblotted with phospho-tyrosine and AXL antibodies. Antibody heavy chain is shown as a 943 
loading control for immunoprecipitation. G) The chart represents the percentage of AXL-positive 944 
cells in six NSCLC patient tumors. Tumor-derived single-cell suspension was stained with 945 
antibodies against CD45, CD31, EpCAM, and AXL. CD45-; CD31-; EpCAM+ cells were then 946 
FACS sorted for the AXL-positive populations. Each bar represents mean ± SD of three technical 947 
replicates. 20,000 cells were analyzed by FACS for each replicate of each sample. Schematic of 948 
the FACS sorting is presented in Figure 1-figure supplement 2H) Expression of AXL and GAS6 949 
genes in FACS-sorted AXL–negative (Blue) and AXL-positive (Red) cells from five human 950 
primary NSCLC tumors. mRNA expression was quantified by Cells to CT one-step SYBR-green-951 
based RT-qPCR. The expression of an indicated mRNA in the AXL-positive cells was calculated 952 
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relative to its expression in AXL-negative cells from the respective tumor. Each dot represents 953 
mean ± SD of three replicates.  954 
 955 
Figure 1-figure supplement 1: FACS sorting algorithm utilized to sort human tumors 956 
Single-cell suspensions generated from resected primary NSCLC were stained with antibodies 957 
against CD45, CD31, EpCAM and AXL. CD45-; CD31-; EpCAM+ cells were then FACS sorted 958 
according to the immune types AXL –ve and AXL-positive (shown in red). Isotype controls were 959 
used to determine negative populations for each antibody staining. 960 
 961 
Figure 2: Pre-existing AXL-positive cells have characteristics of Erlotinib resistant cells. 962 
A) The chart represents the number of viable cells in PC9, PC14 and AXL-positive cells sorted 963 
from PC9 upon treatment with indicated doses of Erlotinib. Values are normalized relative to 964 
vehicle-treated cell (control). Cells were grown for 120 hours in the presence of the drug; the 965 
number of cells was estimated upon staining with the crystal violet, de-staining in 100 µl of 10% 966 
acetic acid and reading absorbance at 590 nm. Diamonds and black bars represent single point 967 
measurements and the mean respectively (n=6); (p-value *< 0.05, ** < 0.005, *** < 0.0005, 968 
unpaired t-test). B) AXL-positive cells are characterized by mesenchymal features such as an 969 
increase in stress fibers. AXL–negative and AXL-positive cells sorted from PC9 were stained F-970 
actin with Phalloidin (green). DAPI (blue) was used as a counter-stain. C) The charts represent 971 
the relative expression of the indicated mesenchymal signature genes in H1650, H1650-M3 and 972 
cells sorted based on surface expression of AXL from H1650 and PC9. Expression of an 973 
indicated mRNA in the AXL-positive cells was calculated relative to its expression in AXL-974 
negative control cells mRNA expression was quantified by SYBR-green-based RT-qPCR. Each 975 
bar represents mean ± SD of 3 replicates from two independent experiments.  (p-value *< 0.05, 976 
** < 0.005, *** < 0.0005, **** < 0.00005, unpaired t-test). D) Expression of mesenchymal 977 
signature genes VIM, TWIST and ZEB1 in FACS-sorted AXL-negative (Blue) and AXL-positive 978 
(Red) cells from five human primary NSCLC tumors. mRNA expression was quantified by Cells 979 
to CT one-step SYBR-green-based RT-qPCR. The expression of an indicated mRNA in the AXL-980 
positive cells was calculated relative to its expression in AXL-negative cells from the respective 981 
tumor. Each dot represents mean ± SD of three replicates.  982 
 983 
Figure 2-figure supplement 1:  984 
The charts represent changes in the distribution of AXL+ and AXL- cell populations at different 985 
Erlotinib concentrations. Panels A) and B) indicate variation in the ratio of AXL+ and AXL- cells 986 
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expressed as a percentage of the total number of cells. The charts in panels C) and D) indicate 987 
changes in the total number of GFP+ and GFP- cells in untreated cells and in cells treated with # 988 
of Erlotinib. FACS sorted AXL+/GFP+ H1650 (panel A) and AXL+/GFP+ PC9 cells were plated 989 
in 96-well plates mixed with approximately equal percentage with AXL-/GFP- H1650 (A) or PC9 990 
(B) as shown. Cells were then grown in the presence of different concentrations of Erlotinib as 991 
indicated. The number of GFP+ and GFP- cells was determined by FACS GUAVA 72 hours after 992 
treatment. A maximum of 6000 cells was analyzed per each well.  Each dot represents mean ± SD 993 
of eight replicates. The experiment was repeated twice with similar results. The lower panels 994 
represent changes in the number of GFP+ cells (red) and GFP- cells (blue). (p-value *< 0.05 and 995 
**** < 0.00005, unpaired t-test) 996 
 997 
Figure 2-figure supplement 2: Pre-existing AXL-positive cells have characteristics of Erlotinib 998 
resistant cells. A) and B) Pre-existent AXL-positive cells preferentially persist during drug 999 
treatment. The charts represent the percentage of viable cells in the indicated populations upon 1000 
treatment with Erlotinib (0,5 M) (A) and Gefitinib (1M) (B). AXL-positive cells were sorted 1001 
from PC9, and stably infected with lentivirus expressing Td-Tomato. Then AXL-negative and 1002 
Td-Tom AXL-positive cells were mixed in the mentioned ratio and treated with the EGFR TKIs. 1003 
Please see the methods section for further details. C) AXL-negative and AXL-positive FACS-1004 
sorted cells from H1650; parental H1650 and erlotinib selected AXL-positive H1650-M3 cells; 1005 
PC9 and erlotinib selected AXL-positive PC14 cells were stained with Phalloidin (green) to 1006 
highlight stress fibers. DAPI (blue) was used as a counter-stain. D) The chart represents the 1007 
relative expression of the indicated mesenchymal signature genes in cells sorted based on surface 1008 
expression of AXL from HCC827. Expression of an indicated mRNA in the AXL-positive cells 1009 
was calculated relative to its expression in AXL-negative control cells mRNA expression was 1010 
quantified by SYBR-green-based RT-qPCR. Each bar represents mean ± SD of 3 replicates from 1011 
two independent experiments.  (p-value *< 0.05, ** < 0.005, *** < 0.0005, **** < 0.00005, 1012 
unpaired t-test). E) Pharmacological inhibition of AXL leads to significant mesenchymal to 1013 
epithelial transition specifically in AXL-positive cells. The charts represent the expression of E-1014 
cadherin and Vimentin in AXL-positive (H1650-M3) cells and AXL-negative (H1650) cells upon 1015 
treatment with the AXL inhibitor BMS-777607 at the indicated concentration. mRNA expression 1016 
was quantified by SYBR-green-based RT-qPCR. Each bar represents mean ± SD of 3 replicates 1017 
from two independent experiments.  (p-value *< 0.05, unpaired t-test). ns = non-significant.  1018 
 1019 
Figure 2-figure supplement 3: AXL-positive cells are a unique cell population. 1020 
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A) The table summarizes the molecular characteristics of the indicated panel of NSCLC cell 1021 
lines. B) The cells were stained with antibodies against E-cadherin (RED) and Vimentin (Green) 1022 
to verify their epithelial or mesenchymal cell state. DAPI (blue) was used as a counter-stain. C) 1023 
Flow cytometry-based analysis of surface expression of AXL in the panel of NSCLC cell lines to 1024 
determine the percentage of pre-existing AXL-positive cells. Monoclonal antibody against N-1025 
terminal of AXL was used for the FACS analysis. Isotype control was used for identifying AXL-1026 
negative population. Isotype control was used for identifying AXL-negative population (not 1027 
shown). 1028 
 1029 
Figure 3: AXL-positive cells are generated stochastically. 1030 
A) If AXL-positive cells (red) were generated as a consequence of genetic mutations, single-cell-1031 
derived clones will have different percentages of AXL-positive cells. B) On the other hand, if 1032 
AXL-positive cells were generated stochastically, then an equal percentage of AXL-positive cells 1033 
will be present in both parental and single cell-derived isogenic clones. C) and D) The charts 1034 
represent the percentage of AXL-positive cells in the parental and single cell-derived clonal 1035 
populations in H1650 and HCC827 respectively. Cells were stained for surface expression of 1036 
AXL, followed by flow cytometry analysis. Each bar represents mean ± SD of three technical 1037 
replicates from two independent experiments. 20,000 cells were analyzed by FACS for each 1038 
replicate of each sample. E) AXL negative (Blue) and AXL-positive (Red) cells were sorted from 1039 
the H1650 cell line and were grown for 18 weeks. The percentage of AXL-positive cells 1040 
emerging in each population was measured weekly and represented as dots in the chart. The red 1041 
dotted line represents the percentage of AXL-positive cells that were present in the total H1650 1042 
parent cell line. F) AXL –ve (Blue) and AXL-positive (Red) cells were sorted from a single-cell-1043 
derived clonal cell line from H1650 (H1650 Clone 2) and were grown for 18 weeks. The 1044 
percentage of AXL-positive cells emerging in each population was measured weekly and 1045 
represented as dots in the chart. The red dotted line represents the percentage of AXL-positive 1046 
cells that were present in the total H1650 clone 2 cell line. 1047 
 1048 
Figure 3-figure supplement 1: Parental cell lines and single cell-derived clonal cell lines 1049 
(H1650 and HCC827) are highly similar from a molecular standpoint. The charts represent 1050 
the mRNA expression of AXL and key mesenchymal genes in the parental and single cell-derived 1051 
clonal cell lines (H1650 and HCC827). 1052 
 1053 
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Figure 4: miRNA profiling reveals a distinct signature that characterizes the AXL-positive 1054 
cell state. 1055 
A) and B) The bubble charts show miRNAs that were >2 fold upregulated or >2 fold down-1056 
regulated in AXL-positive (H1650-M3) cells relative to the parental AXL-negative (H1650) cells. 1057 
Small RNA libraries were generated from each cell line and sequenced using an Illumina 1058 
platform. The size of the bubble represents the abundance of the miRNA. C) Heat map depicts 1059 
patterns of miRNA expression in AXL-negative (H1650) and AXL-positive (H1650-M3) cells, 1060 
validated by quantitative stem-loop RT-PCR. Columns indicate relative expression changes 1061 
compared to U6 snRNA. Each square represents the average of 3 independent measurements. p-1062 
value ≤0.0001, unpaired t-test. D) miR-335 targets are increasingly expressed in AXL-positive 1063 
cells. The heat map on the left shows changes in mRNA expression of miR-335 targets in AXL-1064 
negative (H1650) and AXL-positive (H1650-M3) cells. Each column represents changes in 1065 
mRNAs expression relative to Actin. Each square represents the average of 3 independent 1066 
measurements. p-value ≤0.0001, unpaired t-test. E) The chart represents the expression of miR-1067 
335 normalized to SNORA66 in the indicated cell lines. miRNA expression was quantified by 1068 
ExiLENT SYBR-green-based RT-qPCR. Each bar represents mean ± SD of 3 replicates from two 1069 
independent experiments.  (p-value *< 0.05, unpaired t-test). F) The chart represents expression 1070 
of miR-335 normalized to SNORA66 in AXL –ve (Blue) and AXL-positive (Red) cells sorted 1071 
from H1650 and HCC827 cell lines. miRNA expression was quantified by ExiLENT SYBR-1072 
green-based RT-qPCR. Each bar represents mean ± SD of 3 replicates from two independent 1073 
experiments.  (p-value *< 0.05, unpaired t-test). G) The chart represents expression of miR-335 1074 
normalized to SNORA66 in AXL –ve (Blue) and AXL-positive (Red) cells sorted from four 1075 
human primary NSCLC tumors. miRNA expression was quantified by ExiLENT SYBR-green-1076 
based RT-qPCR. Each dot represents mean ± SD of 3 replicates. H) The chart represents 1077 
expression of the indicated miRNAs normalized to SNORA66 in AXL –ve H1650 cells treated 1078 
with Vehicle (Blue) or TGF-beta (Red). The data are presented as relative to vehicle-treated 1079 
control. miRNA expression was quantified by ExiLENT SYBR-green-based RT-qPCR. Each bar 1080 
represents mean ± SD of 3 replicates from two independent experiments.  (p-value *< 0.05, **< 1081 
0.005, paired t-test). ns= non-significant. I) The chart represents expression of the indicated 1082 
miRNAs normalized to SNORA66 in AXL-positive H1650-M3 cells treated with Vehicle (Red) 1083 
or TGFbRI inhibitor LY2157299, Selleckchem (Red). The data are presented as relative to 1084 
vehicle-treated control. miRNA expression was quantified by ExiLENT SYBR-green-based RT-1085 
qPCR. Each bar represents mean ± SD of 3 replicates from two independent experiments.  (p-1086 
value *< 0.05, **< 0.005, ***< 0.005 paired t-test). ns= non-significant. H) The chart represents 1087 
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expression of the indicated miRNAs normalized to SNORA66 in AXL –ve H1650 cells treated 1088 
with Scramble LNA (Blue) or miR-335 antagomir (Red). The data are presented as relative to 1089 
scramble treated control. miRNA expression was quantified by ExiLENT SYBR-green-based 1090 
RT-qPCR. Each bar represents mean ± SD of 3 replicates from two independent experiments.  (p-1091 
value *< 0.05, **< 0.005, paired t-test).  1092 
 1093 
Figure 4-figure supplement 1: Inhibiting miR-335 expression results in re-expression of 1094 
miR-335 targets. A) The Histogram shows miR-335 levels in H1650 cells upon 5 days of 1095 
treatment with three independent miR-335 antagomirs (see the material section for information) 1096 
in H1650 cells. Levels of miR-335 expression are relative to SNORA66. Each bar represents 1097 
mean ± SD of 3 replicates from two independent experiments. (p-value ** < 0.005, *** < 0.0005 1098 
unpaired t-test). B) Expression of miR-335 targets in H1650 cells upon treatment with miR-335 1099 
antagomirs relative to control. Each bar represents mean ± SD of 3 replicates from two 1100 
independent experiments. (p-value * < 0.05, ** < 0.005, ** < 0.0005, *** <0.00005, # <0.000005 1101 
unpaired t-test). C) The chart represents the relative expression of TGF-1 and 2 in AXL-1102 
negative H1650 cells treated with scramble LNA (Blue) or miR-335 antagomir (Red). The data 1103 
are presented as relative to scramble treated control. mRNA expression was quantified by SYBR-1104 
green-based RT-qPCR. Each bar represents mean ± SD of 3 replicates from two independent 1105 
experiments.  (p-value *< 0.05, paired t-test).  1106 
 1107 
Figure 5: miR-335 regulates AXL-positive cell-state transition. 1108 
A) The chart on left represents the knockdown efficiency of miR-335 antagomir in H1650 and 1109 
PC9 cells. mRNA expression was quantified by SYBR-green-based RT-qPCR and normalized to 1110 
GAPDH. Each bar represents mean ± SD of 3 replicates from two independent experiments. (p-1111 
value * < 0.05, unpaired t-test). B) The chart represents the percentage of AXL-positive cells 1112 
present in H1650 and PC9 cells upon treatment with miR-335 antagomir relative to scramble 1113 
treated control. Cells stained with antibody against N-terminal of AXL were used for FACS 1114 
analysis. Each bar represents mean ± SD of three technical replicates. 20,000 cells were analyzed 1115 
by FACS for each replicate of each sample. (p-value * < 0.05, unpaired t-test). See Figure 5-1116 
figure supplement 1A for representative FACS profiles. C) Representative images of H1650 and 1117 
PC9 cells stained with Phalloidin (green) and DAPI (blue) as counterstain. Cells were treated for 1118 
5 days with control antagomir or miR-335 antagomir. D) Fold change in genes that characterize 1119 
the AXL-positive cell-state upon inhibition of miR-335 in AXL –ve cell lines H1650 and PC9. 1120 
mRNA expression was quantified by SYBR-green-based RT-qPCR and normalized to actin. Each 1121 
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bar represents mean ± SD of 3 replicates from two independent experiments. (p-value * < 0.05, 1122 
** < 0.005, ***< 0.0005 unpaired t-test). E) The charts represent the number of viable cells in 1123 
H1650 and F) PC9 cells upon transfection with miR-335 antagomir and treatment with indicated 1124 
doses of Erlotinib. Values are normalized relative to vehicle-treated cell (control). Cells were 1125 
grown for 120 hours in the presence of the drug; the number of cells was estimated upon staining 1126 
with the crystal violet, de-staining in 100 µl of 10% acetic acid and reading absorbance at 590 1127 
nm. Diamonds and black bars represent single point measurements and the mean respectively 1128 
(n=8); (p-value ** < 0.005, unpaired t-test). ns = non-significant. F) Representative pictures of a 1129 
cell viability assay by crystal violet staining. Cells (H1650, H1650-M3, PC9 and PC14) were 1130 
plated in 24-well plates and transfected with miR-183 and miR-335 mimic oligonucleotides or 1131 
with the transfecting agent RNAiMAX alone as indicated. The cells were then stained with 1132 
crystal violets 96 hours after transfection. Quantification of the experiment is provided in Figure 1133 
5-Figure supplement 3.  1134 
 1135 
Figure 5-figure supplement 1: Inhibiting miR-335 expression results in molecular and 1136 
phenotypic changes characteristic of the AXL-positive cell-state. 1137 
A) Flow cytometry-based analysis of surface expression of AXL in PC9 and H1650 cells upon 1138 
inhibition of miR-335 with miR-335 antagomir, to determine the change in percentage of AXL-1139 
positive cells. Monoclonal antibody against the N-terminal of AXL was used for the FACS 1140 
analysis. Isotype control was used for identifying the AXL-negative population. Isotype control 1141 
was used for identifying the AXL-negative population (not shown).  1142 
 1143 
Figure 5-figure supplement 2: CRISPR-CAS9 mediated gene editing to reduce miR-335 1144 
expression results in molecular and phenotypic changes characteristic of the AXL-positive 1145 
cell-state. 1146 
A) The chart represents the knock-down efficiency of the indicated small guide RNAs (sg. RNA) 1147 
targeting the miR-335 sequence, compared to cells receiving sg.Renilla (control). mRNA 1148 
expression was quantified by SYBR-green-based RT-qPCR. Each bar represents mean ± SD of 3 1149 
replicates from two independent experiments.  (p-value **< 0.005, paired t-test). B) Flow 1150 
cytometry-based analysis of surface expression of AXL in H1650 cells upon editing the miR-335 1151 
sequence with three different guide RNAs, to determine the change in percentage of AXL-1152 
positive cells. sg.RNA against Renilla is used as a control. Monoclonal antibody against N-1153 
terminal of AXL was used for the FACS analysis. Isotype control was used for identifying AXL-1154 
negative population. Isotype control was used for identifying AXL-negative population (not 1155 
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shown). C) The chart represents the fold change in the mRNA expression of the indicated genes 1156 
in H1650 cells containing sg. RNAs targeting the miR-335 sequence or Renilla (control), and 1157 
presented relative to Renilla control. mRNA expression was quantified by SYBR-green-based 1158 
RT-qPCR. Each bar represents mean ± SD of 3 replicates from two independent experiments.  (p-1159 
value *< 0.05, **< 0.005, paired t-test). 1160 
 1161 
Figure 5-figure supplement 3: 1162 
The charts represent the quantification of a cell viability assay by crystal violet illustrated in 1163 
Figure 5-F. Indicated cells (H1650, H1650-M3, PC9, and PC14) were plated in 24-well plates 1164 
transfected with the indicated miRNAs and as control with the transfecting agent RNAiMAX at 1165 
different concentrations. Cells were stained with crystal violets 96 hours after transfection. Each 1166 
bar represents the mean of ± SD of 3 replicates from two independent experiments.  (p-value *< 1167 
(p-value *< 0.05, ** < 0.005, *** < 0.0005, **** < 0.00005, 2way ANOVA, Dunnett’s multiple 1168 
comparison test) 1169 
 1170 
 1171 
Figure 6: Methylation of MEST isoform 2 promoter modulates miR-335 expression in AXL-1172 
positive cells. 1173 
A) Schematic of MEST locus organization and the methylation analysis by bisulfite sequencing 1174 
of MEST CpG island 1 and 2 in AXL –ve (H1650) and AXL-positive (H1650-M3) cells lines 1175 
(lower panel). Each box indicates a CpG dinucleotide and each line of boxes represents the 1176 
analysis of a single cell. The color of each box indicates the methylation of each CpG island. B) 1177 
Semi-quantitative RT-PCR analysis of methylation status of CpG island 1 in H1650 and H1650-1178 
M3. U: Unmethylation-specific primer; M: Methylation-specific primer. See Figure 6-figure 1179 
supplement 1A for the relative amount of methylation of MEST CpG island 1 in the Erlotinib 1180 
naïve and resistant cell lines quantified via methylation-specific SYBR-green-based RT-qPCR 1181 
(MSP). C) The chart represents the relative amount of methylation of MEST CpG island 1 in 1182 
AXL –ve (Blue) and AXL-positive (Red) cells sorted from H1650 and PC9 cell lines. The 1183 
amount of methylation of DNA was quantified via methylation-specific SYBR-green-based RT-1184 
qPCR (MSP). Each bar represents mean ± SD of 3 replicates from two independent experiments.  1185 
(p-value *< 0.05, unpaired t-test). D) The chart represents the relative amount of methylation of 1186 
MEST CpG island 1 in AXL –ve (Blue) and AXL-positive (Red) cells sorted from 4 human 1187 
primary NSCLC tumors. The amount of methylation of DNA was quantified via methylation-1188 
specific SYBR-green-based RT-qPCR (MSP). Each dot represents mean ± SD of three 1189 
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replicates. E-H) Treatment of cells with 5-Aza-dC for is sufficient to reduce the levels of CpG 1190 
island 1 methylation, increase the expression of miR-335, decrease AXL-positive cells and reduce 1191 
Erlotinib resistance, respectively. E) The chart represents the relative amount of methylation of 1192 
MEST CpG island 1 in H1650 and H1650-M3 cells treated with the indicated amount of 5-Aza-1193 
dC for 36 hours. The amount of methylation of DNA was quantified via methylation-specific 1194 
SYBR-green-based RT-qPCR (MSP). Each bar represents mean ± SD of 3 replicates from two 1195 
independent experiments. (p-value *< 0.05, unpaired t-test). ns = non-significant. F) The chart 1196 
represents the amount of miR-335 (relative to SNORA66) in H1650 and H1650-M3 cells upon 1197 
treatment with 5-Aza-dC for 36 hours and normalized to vehicle-treated control. miRNA 1198 
expression was quantified by ExiLENT SYBR-green-based RT-qPCR. Each bar represents mean 1199 
± SD of 3 replicates from two independent experiments. (p-value *< 0.05, unpaired t-test). ns = 1200 
non-significant. G) The chart represents the percentage of AXL-positive cells in H1650-M3 upon 1201 
treatment with 5-Aza-dC for 96 hours, in presence of scramble LNA (RED solid bar) or miR-335 1202 
antagomir (dotted bar). The data is presented relative to H1650-M3 cells treated with scramble 1203 
LNA at 0nM 5-Aza-dC. Cells stained with the antibody against N-terminal of AXL were used for 1204 
FACS analysis. Each bar represents mean ± SD of three technical replicates. 20,000 cells were 1205 
analyzed by FACS for each replicate of each sample. (p-value * < 0.05, ** < 0.005, *** < 0.05 1206 
unpaired t-test). ns = non-significant. See Figure 6-figure supplement 1C for the representative 1207 
mRNA expression. H) The chart represents the relative number of Erlotinib surviving cells in 1208 
absence of the presence of 5-Aza-dC. Each bar represents mean ± SD of 3 replicates from two 1209 
independent experiments. (p-value *< 0.05, unpaired t-test). ns = non-significant.  1210 
 1211 
Figure 6-figure supplement 1: A) The chart represents the relative amount of methylation of 1212 
MEST CpG island 1 in the H1650, H1650-M3, PC9 and PC14 cell lines. The amount of 1213 
methylation of DNA was quantified via methylation-specific SYBR-green-based RT-qPCR 1214 
(MSP). Each bar represents mean ± SD of 3 replicates from two independent experiments.  (p-1215 
value *< 0.05, unpaired t-test). B) The chart represents the relative amount of methylation of 1216 
MEST CpG island 1 in AXL –ve (Blue) and AXL-positive (Red) cells sorted from HCC827 and 1217 
A549 cell lines. The amount of methylation of DNA was quantified via methylation-specific 1218 
SYBR-green-based RT-qPCR (MSP). Each bar represents mean ± SD of 3 replicates from two 1219 
independent experiments.  (p-value *< 0.05, unpaired t-test). C) Crystal violet colorimetric assay 1220 
showing the viability of H1650 and H1650-M3 cell lines (left panel) and PC9, PC14 (right panel) 1221 
upon treatment with different concentrations of 5-Aza-dC for 96h.  D) Quantification of crystal 1222 
violet staining with a microplate endpoint absorbance reader at a wavelength of 590nm. The 1223 
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untreated cells in the first well (0nM) were used as a control to normalize the absorbance of 1224 
viable cells (100% viability), while all results were normalized to the negative control (media 1225 
only) for each individual experiment. The figure is the representation of one out of three 1226 
individual experiments. Error bars indicate SEM. E) The chart represents the relative expression 1227 
of AXL mRNA in H1650-M3 upon treatment with 5-Aza-dC for 36 hours, in presence of 1228 
scramble LNA (RED solid bar) or miR-335 antagomir (dotted bar). The data is presented relative 1229 
to H1650-M3 cells treated with scramble LNA at 0nM 5-Aza-dC. mRNA expression was 1230 
quantified by SYBR-green-based RT-qPCR. Each bar represents mean ± SD of 3 replicates from 1231 
two independent experiments. (p-value * < 0.05, ** < 0.005, *** < 0.0005, unpaired t-test). ns= 1232 
non-significant. F) The chart represents the percentage of AXL-positive cells in AXL–ve cells 1233 
(Blue) and AXL-positive cells (Red) sorted from H1650 upon treatment with 5-Aza-dC for 96 1234 
hours. (p-value ** < 0.005, unpaired t-test). ns = non-significant. 1235 
 1236 
Figure 7: Cancer cells can transit between an epithelial state characterized by low expression of 1237 
AXL and a mesenchymal-like state with high AXL expression. AXL-positive cells have 1238 
increased resistance to EGFR TKi compared to AXL-negative cells. The transition between these 1239 
two states is restricted by miR-335 whose expression is regulated epigenetically through promoter 1240 
methylation. The existence of this innate stochastic/epigenetic mechanism has important 1241 
therapeutic implications. Upon treatment with EGFR TKi, AXL-positive cells can survive but 1242 
differently from cells that have acquired resistance through genetic mutations with time they can 1243 
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Figure 2-gure supplement 1
A B
C D






















































































































Figure 2-gure supplement 2
D
Axl 0    : 0% Axl +ve cells
Axl 10  : 10% Axl +ve cells
Axl 50  : 50% Axl +ve cells
Axl 90  : 90% Axl +ve cells

































































































































































































































































































































Figure 5-figure supplement 1
A FACS profile for 1650 and pc9 + LNA
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Figure 5-gure supplement 3
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